Syneron Bio closed a $150 million Series B to support its macrocyclic peptide development platform, months after securing a multibillion-dollar biobucks deal with AstraZeneca and raising nearly $100 million last year. The funding is aimed at advancing peptide discovery and development capabilities. The company’s platform focus reflects continued investor interest in macrocyclic peptides as a route to improve potency and pharmacokinetics while expanding target tractability across oncology and other therapeutic areas. Syneron’s previous AstraZeneca partnership underscores that large pharma continues to look to peptide technologies for differentiated modalities. For the biotech pipeline, the new financing strengthens near-term platform execution capacity and can translate into faster program progression.